Market Overview

UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

Related BMRN
BioMarin Pharma Crashed This Week, So Why Is This Mega-Bank Still Bullish?
FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
FDA Panel Seen As Bad For BioMarin, Good For Sarepta (Investor's Business Daily)

Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Hold to Buy and announced a $67.00 price target.

Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701 expansion cohort data remains limited, we believe the pipeline provides multiple additional sources of optionality to drive upside in FY13. We believe the company represents an attractive acquisition candidate near-term while also being one of the few (if any) names that seemingly has a sustainable pathway in place to independently achieve large-cap status longer-term."

BioMarin Pharmaceutical closed at $54.08 on Friday.

Latest Ratings for BMRN

Nov 2015Goldman SachsInitiates Coverage onBuy
Nov 2015OppenheimerInitiates Coverage onPerform
Nov 2015OppenheimerInitiates Coverage onPerform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (BMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters